News

Researchers at the Whitehead Institute have created a promising mouse model to study embryonic development, and one that has the potential to serve as a model for neurological diseases such as Parkinson’s and cancers such as melanoma. The study describes the engineering and development of the mouse-human chimera, or mice…

Interest in the potential of stem cell therapy to treat a variety of neurological conditions, including Parkinson’s disease (PD), has been growing for several years, but the question remains: how close are these treatments to clinical use? A new article in the journal Acta Neurologica Scandinavica explored whether stem cell…

In a new editorial published in JAMA Neurology, Dr J. Eric Ahlskog argues that ongoing aerobic exercise should be included in the physical and occupational therapy component of Parkinson’s disease (PD) treatment, since substantial evidence has suggested vigorous exercise is of considerable benefit to patients. Dr.

Men who have higher levels of circulating uric acid (urate) may be less likely to develop Parkinson’s disease, possibly due to the protective role of urate in brain cells, researchers reported. The study, “Prospective study of plasma urate and risk of Parkinson disease in men and women,” was published in Neurolog…

GyroGear, a medical device invention and development company currently based at Imperial College London, is developing an assistive device for Parkinson’s disease patients called the GyroGlove that is intended to stabilize and improve hand movement. GyroGlove development is the current central focus of the GyroGear group,whose  development team of engineers, designers and medics…

Physiotherapy and occupational therapy do not improve the quality of life for patients with mild to moderate Parkinson’s disease (PD), according to a new study published in JAMA Neurology. The findings were based on a large-scale clinical trial, PD REHAB, conducted by researchers at the…

Simvastatin, a cholesterol lowering drug, will be investigated as a potential treatment option for Parkinson’s disease (PD) patients. Researchers hope this drug might one day effectively treat the disease. The double-blinded placebo-controlled clinical trial, in development at the Plymouth University Peninsula Schools of Medicine and Dentistry, plans to enroll up to 198 PD patients at 21 U.K. centers. Researchers are considering…

A novel determinant for Parkinson’s Disease as been discovered: a previously unknown defect in the function of the Pla2g6 protein leads to calcium homeostasis disruption and neuronal cell death. The research paper, entitled “Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson’s disease,” was published in Nature Communications. While…

A drug typically prescribed for dementia may help prevent debilitating falls in people with Parkinson’s disease, according to a study, “Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial,” published in the journal The Lancet Neurology. Falls are a frequent…

An analysis from business intelligence provider GBI Research titled “Frontier Pharma: Parkinson’s Disease — Identifying and Commercializing First-in-Class Innovation,” claims the current Parkinson’s disease (PD) treatment market relies on neuromodulators, and even though symptoms might be soothed, no neuromodulator has demonstrated neuroprotective properties to prevent or even slow…